| CAS NO: | 203915-59-7 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 513.6 |
| Cas No. | 203915-59-7 |
| Formula | C21H27N3O8S2 |
| Synonyms | Matrix Metalloproteinase Inhibitor II,NHDDPC,PG 117025,PGE 4410186 |
| Solubility | ≤0.5mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide |
| Chemical Name | hexahydro-N-hydroxy-1,3-bis[(4-methoxyphenyl)sulfonyl]-5,5-dimethyl-2-pyrimidinecarboxamide |
| Canonical SMILES | COC1=CC=C(S(N2CC(C)(C)CN(S(C3=CC=C(OC)C=C3)(=O)=O)C2C(NO)=O)(=O)=O)C=C1 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
MMP Inhibitor II is a potent, reversible and broad-range inhibitor of matrix metalloproteinases (MMPs) with IC50 values of 24 nM, 18.4 nM, 30 nM and 2.7 nM for MMP-1, MMP-3, MMP-7 and MMP-9, respectively [1].
MMPs belong to a family of at least fifteen secreted and membrane-bound zinc-endopeptidases. MMPs have been engaged in several pathological processes, including tumor growth and metastasis, arthritis, multiple sclerosis, and periodontal disease. These enzymes play a vital role in tissue repair and remodeling via degrading all the extracellular matrix components, including fibrallar and non-fibrallar collagens, laminin, fibronectin, and basement membrane glycoproteins, which enables cell migration. In addition, MMPs exert function in metastasis by promoting tumor invasion and angiogenesis. It was shown that the expression of various members of the MMP family by tumors is closely associated with their proliferative and invasive behavior and metastatic potential. Furthermore, MMPs are broadly sub-divided into three classes: stromelysins, gelatinases, and collagenases, which are secreted in a proenzyme form and require activation to digest an extracellular matrix [1].
In vitro: Up to now, in vitro study of MMP Inhibitor II is still in the development stage.
In vivo: Up to now, in vivo study of MMP Inhibitor II is still in the development stage.
Reference:
[1]. Slawomir M. Wojtowicz-Praga, Robert B. Dickson and Michael J. Hawkins. Matrix metalloproteinase inhibitors. Investigational New Drugs. 1997; 15: 61–75.
m.cnreagent.com